The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
JohnsonD.H.FehrenbacherL.NovotnyW.F.Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol.2004; 22(11): 2184–2191.
2.
SandlerA.GrayR.PerryM.C.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med.2006; 355(24): 2542–2550.
3.
RamalingamS.S.DahlbergS.E.LangerC.J.Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group trial 4599. J Clin Oncol.2008; 26(1): 60–65.
4.
SocinskiM.A.ScappaticciF.A.SamantM.KolbM.KozloffM.F.Safety and efficacy of combining sunitinib with bevacizumab+paclitaxel/carboplatin in non-small-cell lung cancer. J Thorac Oncol.2010; 5(3): 354–360.
5.
SocinskiM.A.CrowellR.HensingT.E.Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest.2007; 132(3): 277S–289S.
AzzoliC.G.BakerS.JrTeminS.American Society of Clinical Oncology Clinical Practice Guideline update of chemotherapy for stage IV non-mallell lung cancer. J Clin Oncol.2009; 27(36): 6251–6266.
8.
CheungY.W.CradockJ.C.VishnuvajjalaB.R.FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44(1): 124–130.
KrisM.G.HeskethP.J.SomerfieldM.R.; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
GelingO.EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
15.
TerreyJ.P.AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
16.
CarmichaelJ.KeizerH.J.CupissolD.MilliezJ.ScheidelP.SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
17.
de WitR.de BoerA.C.vd LindenG.H.StoterG.SparreboomA.VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
18.
SmithIE. Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
19.
SoukopM. Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer.1994; 2(3): 177–183.
20.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(suppl 1): 26–31.
21.
DuBoisA.VachW.KiechleM.Cramer-GiraudU.MeerpohlH.G.Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis. Oncology.1996; 53(suppl 1): 26–31.
22.
CornelisonT.L.ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
23.
WeissR.B.DonehowerR.C.WiernikP.H.Hypersensitivity reactions from Taxol. J Clin Oncol.1990; 8(7): 1263–1268.
SmithT.J.KhatcheressianJ.LymanG.H.2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
KintzelP.E.DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
32.
CalvertA.H.NewellD.R.GumbrellL.A.Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol.1989; 7(11): 1748–1756.
33.
CalvertA.H.BoddyA.BaileyN.P.Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol.1995; 22(suppl 12): 91–8.
34.
AronoffG.R.BennettW.M.BernsJ.S.Drug Prescribing in Renal Failure.5th ed.Philadelphia, PA: American College of Physicians; 2007.
35.
FloydJ.MirzaI.SachsB.PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
36.
KingP.D.PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6: 162–176.
